Latest filing published 01 May 2026 for Immunovant, Inc., €58k.
Filing timeline
BuySaleInsider track record
No signal scores available.
Robert Graham Susman: trading record in brief
Robert Graham Susman (senior executive) discloses dealings in Immunovant, Inc. to SEC (Form 4). Over a trading history stretching from 1 May 2025 to 1 May 2026, the count stands at 3 filings.
The open-market record consists of 1 sale worth €58k, with no purchase. Other entries cover 2 share grants. In 2026 alone, the filings show no purchases and 1 sale.
On 1 May 2026 came the latest disclosure, an open-market sale for €58k in Immunovant, Inc. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Robert Graham Susman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,502 shares@ US$27.170.0007% mcap100.0% of flowCommon StockSEC:0001764013-26-000058:0
- 13,880 shares0Common StockSEC:0001764013-26-000042:0
- 25,016 shares0Common StockSEC:0001415889-25-012045:0
3 of 3 declarations
